Real-World Treatment Patterns and Patient reported outcome in COPD (REMIND) - REMIND

Study identifier:D5980R00080

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A secondary database study using COPD cohort study in Japan to investigate health status of COPD patients with different inhaler treatment

Medical condition

COPD

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual enrollment

708

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 31 Aug 2023

Estimated Primary Completion Date: 31 Jan 2024

Estimated Study Completion Date: 31 Jan 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2023 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
LAMA	-
LAMA plus LABA	-
ICS plus LABA	-

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]